DDInter1293 DDInter1376
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
Nilotinib {u} (Compound) binds {v} (Gene) CA7
Nilotinib {u} (Compound) upregulates {v} (Gene) HERPUD1
Nilotinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Nilotinib {u} (Compound) downregulates {v} (Gene) BNIP3
Nilotinib {u} (Compound) causes {v} (Side Effect) Lymphopenia
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methysergide
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Nilotinib (Compound) treats hematologic cancer (Disease)
Nilotinib (Compound) binds CA7 (Gene)
Nilotinib (Compound) upregulates HERPUD1 (Gene)
Nilotinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Nilotinib (Compound) downregulates BNIP3 (Gene)
Nilotinib (Compound) causes Lymphopenia (Side Effect)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Methysergide